Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks.

Under the auspices of the Saudi Society of Rheumatology, Saudi Society of Dermatology and Dermatologic Surgery, Saudi ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Occupational contact dermatitis was common among construction workers, with metals, epoxy resin, and rubber identified as common etiological sources.

A similar prevalence of acrylate sensitization was found among patients who were pre- and postimplantation of dental or orthopedic prostheses.

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Revolutionizing Home and Commercial Cleaning with Aqueous Ozone Solutions that are hypoallergenic & eco-friendly ...